Assenagon Asset Management S.A. Reduces Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Assenagon Asset Management S.A. reduced its stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 16.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 323,376 shares of the company's stock after selling 62,044 shares during the period. Assenagon Asset Management S.A. owned approximately 0.08% of GoodRx worth $1,504,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. nVerses Capital LLC purchased a new position in shares of GoodRx in the 3rd quarter valued at about $33,000. EP Wealth Advisors LLC acquired a new stake in GoodRx in the third quarter valued at approximately $73,000. Dark Forest Capital Management LP purchased a new stake in shares of GoodRx in the second quarter valued at approximately $86,000. Sanctuary Advisors LLC purchased a new stake in shares of GoodRx during the third quarter worth about $85,000. Finally, Deerfield Management Company L.P. Series C purchased a new stake in shares of GoodRx during the second quarter worth about $173,000. Hedge funds and other institutional investors own 63.77% of the company's stock.

GoodRx Trading Up 0.4 %

GDRX traded up $0.02 during mid-day trading on Friday, hitting $4.95. 753,784 shares of the stock were exchanged, compared to its average volume of 1,282,511. The company has a market cap of $1.89 billion, a PE ratio of -165.00, a PEG ratio of 2.38 and a beta of 1.27. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The firm's fifty day moving average is $4.60 and its two-hundred day moving average is $6.36. GoodRx Holdings, Inc. has a 1-year low of $4.09 and a 1-year high of $9.26.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Mizuho started coverage on GoodRx in a report on Wednesday, December 4th. They issued a "neutral" rating and a $5.00 price objective on the stock. Barclays dropped their price target on GoodRx from $10.00 to $6.00 and set an "overweight" rating for the company in a research report on Monday, November 11th. Morgan Stanley decreased their price objective on GoodRx from $7.00 to $6.00 and set an "equal weight" rating on the stock in a report on Tuesday, December 17th. Citigroup decreased their price target on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating on the stock in a research note on Friday, January 10th. Finally, KeyCorp dropped their price objective on shares of GoodRx from $7.00 to $6.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. Five equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, GoodRx presently has an average rating of "Moderate Buy" and a consensus target price of $8.38.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.